Aquestive Therapeutics (NASDAQ:AQST) CEO Sells $753,423.09 in Stock

Aquestive Therapeutics, Inc. (NASDAQ:AQST) CEO Daniel Barber sold 180,677 shares of the business’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $4.17, for a total transaction of $753,423.09. Following the completion of the transaction, the chief executive officer owned 1,004,753 shares in the company, valued at $4,189,820.01. The trade was a 15.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Aquestive Therapeutics Trading Down 0.2%

Shares of NASDAQ:AQST opened at $4.02 on Friday. The company has a 50-day moving average price of $3.99 and a 200-day moving average price of $5.20. The company has a market cap of $490.60 million, a price-to-earnings ratio of -5.15 and a beta of 1.61. Aquestive Therapeutics, Inc. has a 12 month low of $2.12 and a 12 month high of $7.55.

Aquestive Therapeutics (NASDAQ:AQST) last posted its earnings results on Wednesday, March 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13). The company had revenue of $13.02 million during the quarter, compared to the consensus estimate of $13.28 million. As a group, research analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Analyst Ratings Changes

AQST has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen raised Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, Lake Street Capital set a $6.00 price target on shares of Aquestive Therapeutics in a report on Tuesday, February 3rd. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $8.80.

Institutional Trading of Aquestive Therapeutics

Large investors have recently bought and sold shares of the company. NewEdge Advisors LLC purchased a new position in shares of Aquestive Therapeutics during the 3rd quarter worth approximately $28,000. BNP Paribas Financial Markets lifted its stake in shares of Aquestive Therapeutics by 78.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock valued at $31,000 after purchasing an additional 4,134 shares during the period. Modern Wealth Management LLC purchased a new position in shares of Aquestive Therapeutics in the 2nd quarter valued at approximately $33,000. Cox Capital Mgt LLC bought a new stake in shares of Aquestive Therapeutics during the third quarter valued at approximately $59,000. Finally, Kestra Private Wealth Services LLC bought a new stake in shares of Aquestive Therapeutics during the third quarter valued at approximately $60,000. 32.45% of the stock is owned by institutional investors.

Key Aquestive Therapeutics News

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: HC Wainwright issued a more favorable near‑term earnings outlook and raised some FY estimates, offering modest analytical support if operational/regulatory progress continues. HC Wainwright Estimates
• Neutral Sentiment: Coverage pieces (market commentary) explain recent volatility and provide context for regulatory risk tied to Anaphylm; these explain price moves but do not change fundamentals immediately. AAII: Why AQST Is Down
• Neutral Sentiment: Short‑interest figures circulating this week show anomalous zero/NaN values (likely reporting error) and should not be used to support a short‑squeeze thesis until official confirmations are posted. (No authoritative link provided.)
• Negative Sentiment: Multiple law firms have filed or advertised class actions for purchasers between June 16, 2025 and Jan 8, 2026; several solicitations for lead‑plaintiff roles raise the prospect of material litigation costs, management distraction, and downside risk to the stock. Rosen Law Firm Notice
• Negative Sentiment: Additional class‑action notices from other firms (Pomerantz, Faruqi, Bernstein, Portnoy) amplify the legal narrative and extend the timeline of investor uncertainty. Pomerantz Alert
• Negative Sentiment: Insider selling: a disclosed sale (15,741 shares by Sherry Korczynski and other senior officer transactions) at roughly $4.17 reduces insider holdings and is often interpreted negatively by the market. InsiderTrades: Insider Sale
• Negative Sentiment: A PR Newswire item highlights an allegation tied to an analyst’s large price‑target cut (Cantor), linking that cut to a sharp one‑day selloff; this adds to reputational/regulatory narrative around prior communications and approval risk for Anaphylm. PR Newswire: Analyst Lawsuit

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.